Nektar Therapeutics Files 8-K on Financials
Ticker: NKTR · Form: 8-K · Filed: May 9, 2024 · CIK: 906709
Sentiment: neutral
Topics: financial-condition, results-of-operations, sec-filing
Related Tickers: NKTR
TL;DR
Nektar dropped an 8-K on May 9th detailing their financials. Check it for the latest.
AI Summary
Nektar Therapeutics filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's financial status. Specific financial figures and operational details are available within the document.
Why It Matters
This 8-K filing provides investors with crucial, up-to-date information on Nektar Therapeutics' financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: medium — 8-K filings are routine disclosures, but the specific financial details and operational updates within can reveal significant company performance changes.
Key Players & Entities
- Nektar Therapeutics (company) — Registrant
- May 9, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 455 Mission Bay Boulevard South (address) — Principal Executive Offices
- San Francisco, California 94158 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by Nektar Therapeutics?
The primary purpose of this 8-K filing is to report on Nektar Therapeutics' results of operations and financial condition, and to include financial statements and exhibits.
On what date was this 8-K filing reported?
The date of the report, and the date of the earliest event reported, is May 9, 2024.
In which state is Nektar Therapeutics incorporated?
Nektar Therapeutics is incorporated in Delaware.
What is the address of Nektar Therapeutics' principal executive offices?
The address of Nektar Therapeutics' principal executive offices is 455 Mission Bay Boulevard South, San Francisco, California 94158.
What SEC Act does this filing fall under?
This filing is made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-05-09 16:20:50
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value NKTR Nasdaq Capital Marke
Filing Documents
- ea0205626-8k_nektar.htm (8-K) — 24KB
- ea020562601ex99-1_nektar.htm (EX-99.1) — 65KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-041325.txt ( ) — 269KB
- nktr-20240509.xsd (EX-101.SCH) — 3KB
- nktr-20240509_lab.xml (EX-101.LAB) — 33KB
- nktr-20240509_pre.xml (EX-101.PRE) — 22KB
- ea0205626-8k_nektar_htm.xml (XML) — 3KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On May 9, 2024, Nektar Therapeutics, a Delaware corporation ("Nektar"), issued a press release (the "Press Release") announcing its financial results for the quarter ended March 31, 2024. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report, including the exhibit hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release titled "Nektar Therapeutics Reports First Quarter 2024 Financial Results" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEKTAR THERAPEUTICS Date: May 9, 2024 By: /s/ Mark A. Wilson Mark A. Wilson Chief Legal Officer and Secretary 2